Glaxo (GSK), Human Genome's (HGSI) Benlysta Wins Backing of FDA Advisory Panel

November 16, 2010 4:58 PM EST Send to a Friend
An FDA panel has recommended approval of GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences (Nasdaq: HGSI) new lupus treatment Benlysta.

As the process goes (from effectiveness to safety to recommendation), the panel first found the drug effective in a 10-5 vote, then, in a 14-1 vote, found that Benlysta was safe. Finally, the panel voted 13-2 to back the lupus treatment.

Benlysta will be the first new lupus drug in more than 50 years.

While shares of Human Genome Sciences have been halted throughout today's trading session (on account of the FDA panel hearing), shares of the massive GlaxoSmithKline are up 2.7% in this evening's after-hours session.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Trader Talk

Add Your Comment